Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$19.45
Change (%) Stock is Down 0.25 (1.27%)
Volume245,891
Data as of 08/18/17 4:00 p.m. ET

Latest News

08/08/17
Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference
08/02/17
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update
08/01/17
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
07/19/17
Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.